Johns Hopkins Will Work With Clearmind On Alcohol Addiction Research Program

Israeli psychedelics biotech Clearmind Medicine CMND has inked a research agreement with Johns Hopkins University School of Medicine (JHU) to conduct the first-in-human Phase I/IIa clinical trial on its proprietary MEAI-based compound CMND-100 for the potential treatment of Alcohol Use Disorder (AUD.) 

Associate psychiatry and behavioral sciences professor at JHU, Jennifer Ellis Ph.D. will be the study’s PI, seconded by the university’s behavioral pharmacology research unit director Prof. Eric Strain.

See Also: Johns Hopkins Researchers Find Psychedelics Reopen The Social Reward Learning Period

CEO Dr. Adi Zuloff-Shani says the team is honored and grateful to collaborate with JHU, “one of the global leaders in psychedelics clinical research and in researching addictions,” toward studying proprietary CMND-100 for the specified condition. 

Clearmind’s CMND-100 clinical program consists of a multinational, multi-center, Phase I/II single- and multiple-dose tolerability, safety and pharmacokinetic study in both healthy volunteers and people with AUD.

"Johns Hopkins is our second US clinical site joining our trial, following Yale School of Medicine’s Department of Psychiatry,” Zuloff-Shani added. “We are excited to be working closely with two of the world’s leading medical centers, who have researched our treatment and agreed to participate in our clinical program."

Besides finding the tolerable dose and characterizing the safety and PK/PD of single and repeated doses of the novel compound, the study also aims to assess the efficacy of CMND-100 in reduction of drinking patterns and cravings in individuals with moderate-to-severe AUD. 

Oral capsules will be administered once a day for ten consecutive days, and patients will report their drinking patterns and craving for alcohol (and cigarettes) during the study period.

More On Clearmind’s Work

The Israel-based company’s IP currently consists of fourteen patent families with the aim of seeking additional patents for its compounds. 

Clearmind has also stated its intent to “remain opportunistic” regarding the acquisition of additional IP to build its portfolio. 

Find out more about the company’s novel alcohol addiction treatment paradigm in Benzinga’s exclusive interview with CEO Dr. Zuloff-Shani.

If you're following the cannabis industry, our upcoming Cannabis Capital Conference is where you ought to be. Whether to close your deals or just get acquainted with the sector’s best, come join us on Sept. 27-28 in Chicago for our 17th edition! Tickets HERE.

Photo: Benzinga edit with photo by Raimundo79 and Sergey Nivens on Shutterstock.